# ABVC BioPharma, Inc

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/ABVC BioPharma, Inc).

## Overview

ABVC BioPharma, Inc. is a Nevada-incorporated, clinical-stage biopharmaceutical company developing plant-derived investigational drugs and a medical device, with programs focused on central nervous system (CNS) disorders and oncology/hematology. Its pipeline comprises seven drug candidates and one device, largely licensed from related parties, and the company’s operating model centers on advancing assets through clinical development and monetizing them via out-licensing and collaborations. To date, ABVC has generated only unsubstantial revenue, primarily from outlicensing intellectual property and providing CDMO services rather than from product sales. The company runs development and partner-facing activities across the U.S. and Asia-Pacific, including clinical collaborations with institutions such as Stanford University Medical Center and Taipei Veterans General Hospital.

## Products & services

• ABV-1504 (MDD) and ABV-1505 (ADHD) botanical drug candidates
• Oncology/hematology pipeline (ABV-1501, ABV-1519, ABV-1702, ABV-1703)
• ABV-1601 (depression in cancer patients) drug candidate
• ABV-1701 Vitargus ophthalmic medical device
• Out-licensing of intellectual property (regional partnering)
• CDMO services (contract development/manufacturing support)

- **CNS botanical drug candidates** (35%) — Plant-derived investigational drugs targeting CNS indications such as MDD and ADHD (e.g., ABV-1504, ABV-1505).
- **Oncology/hematology botanical drug candidates** (25%) — Plant-derived investigational drugs for cancers and hematologic disorders (e.g., ABV-1501, ABV-1519, ABV-1702, ABV-1703, ABV-1601).
- **Medical device (Vitargus)** (10%) — ABV-1701 Vitargus device program for retinal detachment/vitreous hemorrhage treatment pathways.
- **Out-licensing and collaboration income** (20%) — Licensing of ABVC intellectual property and regional partnering arrangements (e.g., BioHopeKing for selected Asian markets).
- **CDMO services** (10%) — Contract development/manufacturing-related services provided to external parties as a source of non-product revenue.

- ABV-1504 (MDD) and ABV-1505 (ADHD) botanical drug candidates
- Oncology/hematology pipeline (ABV-1501, ABV-1519, ABV-1702, ABV-1703)
- ABV-1601 (depression in cancer patients) drug candidate
- ABV-1701 Vitargus ophthalmic medical device
- Out-licensing of intellectual property (regional partnering)
- CDMO services (contract development/manufacturing support)

## Customers

ABVC’s near-term customers are primarily commercial partners rather than end patients, reflecting a business model built around out-licensing and co-development of pipeline assets. Potential counterparties include biotechnology and pharmaceutical companies seeking rights to develop and commercialize ABVC’s CNS and oncology/hematology candidates, as well as the Vitargus device, in specific territories. The company also interacts with research institutions and principal investigators that conduct Phase II trials, which are critical enablers of clinical progress but are not necessarily revenue-generating customers. In addition, ABVC provides CDMO services, implying a customer base of companies that outsource development/manufacturing work. The ability to secure partners—particularly in the U.S.—is a key determinant of whether ABVC can translate clinical assets into recurring licensing milestones/royalties or service revenue.

- **Biopharma licensing partners (U.S.)** (primary) — License or co-develop CNS and oncology/hematology candidates; value is driven by U.S. commercial potential and regulatory pathway execution.
- **Regional commercialization partners (Asia-Pacific)** (primary) — Acquire territorial rights and collaborate on development/commercialization in selected Asian markets (e.g., Taiwan/Asia partners).
- **CDMO customers** (secondary) — Purchase contract development/manufacturing-related services to supplement ABVC’s limited pipeline monetization revenue.
- **Clinical research institutions and investigators** (secondary) — Conduct Phase II trials and generate clinical data needed to attract licensing partners and progress regulatory submissions.

- Pharma/biotech partners licensing ABV-1504/1505 CNS programs for U.S. markets
- Regional partners in Asia (e.g., BioHopeKing) for selected Asian markets
- Pharma/biotech partners seeking oncology/hematology assets for co-development
- Ophthalmology device partners for Vitargus commercialization pathways
- CDMO clients outsourcing development/manufacturing support work
- Academic/clinical institutions running Phase II trials (strategic enablers)

## Geography

ABVC operates with business operations in Taiwan and collaborative activities in the United States and Japan, reflecting its Asia-Pacific sourcing of technologies and U.S.-centric clinical and partnering ambitions. The company reports that sales to customers outside the United States accounted for 100% of sales in both 2025 and 2024, indicating that monetization to date has been entirely international. ABVC’s cost base and cash flows are exposed to currency movements because substantial revenues and expenses are denominated in New Taiwan Dollars and U.S. dollars. The international footprint also increases exposure to cross-border compliance requirements (including anti-corruption and export controls) and to China–Taiwan geopolitical instability, which can affect staffing, partner engagement, and operational continuity.

- Business operations and key employees located in Taiwan
- Collaborative activities with partners in the United States and Japan
- 100% of reported sales were to customers outside the United States (2025, 2024)
- Currency exposure to New Taiwan Dollar and U.S. dollar cash flows
- Cross-border compliance exposure (FCPA, export controls, local pharma regs)
- Geopolitical risk tied to China–Taiwan instability affecting operations/partners

## Strategy

ABVC’s strategy is to build value in a portfolio of plant-derived drug candidates and a medical device by advancing them through clinical milestones and then monetizing via out-licensing and partnerships. The company sources opportunities from research institutions in the Asia-Pacific region, evaluates preclinical and early clinical evidence, and then designs clinical trial plans with principal investigators in the U.S., Australia, and Taiwan to progress assets toward Phase II and beyond. A stated priority is to expand partnerships beyond its existing collaboration for selected Asian markets, particularly by aligning with U.S. commercial partners for key CNS and oncology programs. Given limited product revenue, the strategy also relies on accessing capital and maintaining operational readiness (CRO selection, trial execution, internal controls) to sustain development timelines and partner interest.

- Advance botanical CNS and oncology/hematology assets through clinical stages
- Monetize pipeline via out-licensing and co-development partnerships
- Source/licence technologies from Asia-Pacific research institutions
- Engage principal investigators to execute Phase II trials in key geographies
- Expand partner network beyond current Asian-market collaboration
- Use CDMO services and IP licensing to support near-term cash generation

## Risks

ABVC faces core clinical-stage biotech risks: long development timelines, high R&D spend, and binary outcomes from clinical trials that determine whether assets can be licensed or approved. The company’s business model heightens partnering risk—if it cannot secure or maintain strategic collaborations for candidates that are not fully licensed out, it may need to fund development internally and raise additional capital. International operations add material exposure to regulatory and compliance complexity (including FCPA and local anti-corruption laws), currency fluctuations between the U.S. dollar and New Taiwan Dollar, and China–Taiwan geopolitical instability. Execution risk also includes dependence on CROs and trial sites for data generation and FDA communications, as well as potential disruptions from public health events (e.g., COVID-19) that can slow enrollment and disrupt supply chains. Finally, as a small issuer, it is exposed to financing and listing risks (e.g., Nasdaq compliance) that can constrain capital access.

- **Inability to identify and align with commercial partners (especially in the U.S.)** [high] — ABVC relies on out-licensing/co-development to monetize assets; delays reduce competitiveness and extend cash burn.
- **Licensors may terminate license agreements** [critical] — Pipeline assets are licensed (including from related parties); termination could halt R&D and eliminate future partnering value.
- **International operations and China–Taiwan geopolitical instability** [high] — Operations and key employees are in Taiwan and partners are in Asia; instability can disrupt operations, compliance, and fund transfers.
- **COVID-19 and other public health disruptions** [medium] — Can impair patient recruitment, disrupt supply chains for ABV-1504/1505/1601, and divert management resources.
- **CRO/vendor dependency for clinical development and regulatory interactions** [medium] — Inability to secure capable CROs can delay data generation and FDA communications, reducing partnerability of assets.

- Failure to secure U.S. partners for key pipeline programs delays monetization
- Licensors could terminate license agreements, abruptly ending programs
- Clinical trial execution risk: enrollment, endpoints, and reproducibility
- Dependence on CROs for analysis, lab work, and FDA communications
- International compliance risk (FCPA/anti-corruption, export controls)
- China–Taiwan geopolitical instability impacting Taiwan-based operations
- Currency fluctuations (TWD vs USD) affecting reported results and cash needs
- COVID-19/public health disruptions to trials and supply chains

## Accounting

ABVC’s financial statements are highly sensitive to management estimates because the company is clinical-stage and its reported results can be driven by non-cash items, accruals, and valuation judgments rather than stable product revenue. Revenue recognition requires careful analysis of out-licensing arrangements and CDMO contracts, including whether consideration is contingent on milestones and whether performance obligations are satisfied over time or at a point in time. The company has disclosed restatements and presentation reclassifications (e.g., related-party balances in cash flow presentation), which can affect period-to-period comparability and investors’ assessment of operating vs financing cash flows. Stock-based compensation and other non-cash income/expense items can materially influence reported losses and should be normalized when assessing underlying cash burn. Given international operations, foreign currency translation and transaction gains/losses (USD vs TWD) can add volatility to reported results.

- **Revenue recognition for out-licensing and collaboration arrangements** — Affects revenue timing, deferred revenue/contract assets, and period comparability
- **Revenue recognition for CDMO services** — Affects service revenue timing and gross margin presentation
- **Restatement and cash flow classification/reclassification** — Affects operating vs financing cash flow comparability across periods
- **Use of estimates and non-cash items (including stock-based compensation)** — Affects net loss, operating expense trends, and valuation inputs

- Revenue recognition for out-licensing: milestones, variable consideration
- Revenue recognition for CDMO: over-time vs point-in-time delivery
- High estimation uncertainty typical of clinical-stage operations
- Restatement/reclassification impacts comparability (cash flow presentation)
- Stock-based compensation can materially affect net loss vs cash burn
- Foreign currency (USD/TWD) translation and transaction effects add volatility

---

*Last updated: 2026-09-24T11:15:42.212012+00:00*